5-Methoxy-6-methyl-indan | 1685-78-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-Methoxy-6-methyl-indan
• 英文别名: 5-methoxy-6-methyl-2,3-dihydro-1H-indene
• CAS: 1685-78-5
• 化学式: C₁₁H₁₄O
• 分子量: 162.232
• InChiKey: LDJOSONRJMJPSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-Methoxy-6-methyl-indan 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 6-甲基茚满-5-醇
  参考文献：
  名称：

  Synthesis and antianxiety activity of (.omega.-piperazinylalkoxy)indan derivatives

  摘要：

  A series of (omega-piperazinylalkoxy)indan derivatives has been synthesized and screened for potential antianxiety activities. The effect of structural modification of these molecules on activities has been systemically examined. Antianxiety activity was displayed by 5-[3-(4-phenyl-1-piperazinyl)propoxy]indan (2), 5-[3-[4-(4-fluorophenyl)-1-piperazinyl]-propoxy]indan (8), 6-fluoro-5-[3-(4-phenyl-1-piperazinyl)propoxy]indan (33), and 6-methyl-5-[3-(4-phenyl-1-piperazinyl)propoxy]indan (42), as determined in antifighting and anti-morphine tests. These derivatives in antianxiety tests were equipotent or more potent than chlordiazepoxide with less muscle-relaxant effect. They also showed weak neuroleptic-like action.

  DOI：

  10.1021/jm00356a024
• 作为产物：
  描述：

  6-Methoxy-5-methyl-indan-1-on 在 盐酸 、 锌 作用下， 生成 5-Methoxy-6-methyl-indan
  参考文献：
  名称：

  Munavalli,S., Bulletin de la Societe Chimique de France, 1965, p. 785 - 787

  摘要：

  DOI：

文献信息

• [EN] CXCR3 RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR CXCR3
  申请人：CELGENE INT II SARL

  公开号：WO2018045246A1

  公开（公告）日：2018-03-08

  Compounds are provided having the structure of the following Formula I: where R, R1, R2, R3a and R3b are as defined herein. Pharmaceutical compositions comprising such compounds, as well as methods related to their manufacture and use, are also provided.

  提供具有以下式I结构的化合物：其中R、R1、R2、R3a和R3b如本文所述定义。还提供了包含这些化合物的药物组合物，以及与它们的制造和使用相关的方法。
• PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS
  申请人：Gilead Sciences, Inc.

  公开号：US20130164280A1

  公开（公告）日：2013-06-27

  The invention provides compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections. The compounds and compositions are useful for treating Pneumovirinae virus infection including Human respiratory syncytial virus infections.

  该发明提供了用于治疗病毒感染的化合物、药物可接受的盐和酯以及它们的组合物。这些化合物和组合物对于治疗包括人类呼吸道合胞病毒感染在内的肺病毒亚科病毒感染是有用的。
• [EN] ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS<br/>[FR] ANILINOPYRIMIDINES EN TANT QU'INHIBITEURS DE KINASE 1 PROGÉNITRICES HÉMATOPOÏÉTIQUES (HPK1)
  申请人：ARIAD PHARMA INC

  公开号：WO2018102366A1

  公开（公告）日：2018-06-07

  The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.

  这项发明涉及用于治疗癌症和其他丝氨酸-苏氨酸激酶介导的疾病的HPK1抑制剂，其化学式为：其中A、R1、R2、R3、R4、R5、R6、R16、R17、X1、X2、X3、X4、m和n如本文所述。
• CXCR3 receptor agonists
  申请人：RECEPTOS LLC

  公开号：US11040954B1

  公开（公告）日：2021-06-22

  Compounds are provided having the structure of the following Formula I: where R, R1, R2, R3a and R3b are as defined herein. Pharmaceutical compositions comprising such compounds, as well as methods related to their manufacture and use, are also provided.

  所提供的化合物具有下式 I 的结构： 其中 R、R1、R2、R3a 和 R3b 如本文所定义。此外，还提供了包含此类化合物的药物组合物，以及与其制造和使用相关的方法。
• KIKUMOTO, RYOJI;TOBE, AKIHIRO;FUKAMI, HARUKAZU;EGAWA, MITSUO, J. MED. CHEM., 1983, 26, N 2, 246-250
  作者：KIKUMOTO, RYOJI、TOBE, AKIHIRO、FUKAMI, HARUKAZU、EGAWA, MITSUO

  DOI：——

  日期：——